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formation in protein overload nephropathy
JASON D. COOMBES, ELLEIN MREICH, CHRISTOPHER LIDDLE, and GOPALA K. RANGAN
Kidney Regeneration Laboratory, Centre for Transplant and Renal Research; and Department of Clinical Pharmacology,
Molecular Pharmacology Laboratory, Westmead Millennium Institute, The University of Sydney, Westmead Hospital,
Sydney, Australia
Rapamycin worsens renal function and intratubular cast forma-
tion in protein overload nephropathy.
Background. Rapamycin (sirolimus) is associated with func-
tional nephrotoxicity in some patients with nephrotic glomeru-
lar diseases but the pathophysiologic mechanisms are not
known. This study investigated the effects of rapamycin on renal
function and structure in protein overload nephropathy.
Methods. Rats with protein overload nephropathy [induced
by bovine serum albumin (BSA), 2.1 g by daily intraperitoneal
injection, day 0 to day 3] received daily intraperitoneal injec-
tions of either vehicle [dimethyl sulfoxide (DMSO)], rapamycin
(0.2 mg/kg, an inhibitor of mammalian target of rapamycin), or
roscovitine (3.5 mg/kg, a small molecule cyclin-dependent ki-
nase inhibitor) (N = 9 each) from day −3 to day 3.
Results. In protein overload nephropathy, rapamycin caused
severe acute renal failure and mild hypercholesterolemia (both
P < 0.05). Rapamycin dramatically increased intratubular cast
formation, and proximal tubular epithelial cells were swollen
and engorged with increased cytoplasmic protein droplets. The
number of 5-bromo-2′-deoxyuridine (BrdU)-positive tubular
epithelial cells increased by more than 20-fold on day 3 in pro-
tein overload nephropathy, and this was attenuated by 65% with
rapamycin (P < 0.05), whereas roscovitine was ineffective. Ra-
pamycin increased the protein expression of p27kip1 in tubular
epithelial cells, but did not alter D-type cyclin expression or
apoptosis.
Conclusion. Rapamycin caused a specific pattern of acute
renal injury characterized by increased intratubular cast forma-
tion in protein overload nephropathy. This could be due to dis-
ruption of a potentially important compensatory mechanism in
nephrotic glomerular diseases involving tubular epithelial cell
protein endocytosis and proliferation.
Rapamycin (sirolimus) is a new immunosuppressant
with potent antitumor and antiproliferative properties
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[1, 2]. Preclinical and clinical studies have now firmly es-
tablished rapamycin as an excellent agent in calcineurin
inhibitor–free immunosuppressant regimens to prevent
long-term allograft rejection in solid organ transplantion,
with the potential to reduce chronic allograft nephropa-
thy [3, 4]. Indeed, because of these attributes, rapamycin
also holds promise in the treatment of nephrotic glomeru-
lar diseases [5], such as membranous nephropathy and
focal segmental glomerulosclerosis (FSGS), where cal-
cineurin inhibitor–free regimens are also desperately
needed [6, 7]. However, a recent preliminary study re-
ported that six out of 11 patients with nephrotic glomeru-
lar diseases treated with rapamycin developed functional
nephrotoxicity for unclear reasons [8].
Rapamycin binds to a specific cytosolic protein, FK
binding protein-12, and this complex inhibits the activa-
tion of the mammalian target of rapamycin (mTOR), a
kinase required for cell cycle progression [1, 2]. How-
ever, the antiproliferative actions are not restricted to
T cells, and rapamycin also has these effects in other cell
types, including tubular epithelial cells [9]. In nephrotic
glomerular diseases, tubular epithelial cell proliferation
is increased [10, 11], and this might be a compensatory
mechanism to process the excess plasma proteins present
in the lumen.
The aim of this study was to investigate the func-
tional and pathologic effects of rapamycin in a model
of glomerular disease characterized by heavy proteinuria
and tubular epithelial cell proliferation. Protein overload
nephropathy is induced in rats by the repeated injections
of bovine serum albumin (BSA) and (by mechanisms
that are not entirely clear) this causes nonimmune-
initiated glomerular injury with an almost immediate on-
set of nephrotic range proteinuria [12]. During the first
week, protein overload nephropathy is characterized by
marked tubular epithelial cell proliferation and mild in-
terstitial inflammation [12], making it an excellent in
vivo model to investigate the antiproliferative actions
of rapamycin on tubular epithelial cells in proteinuric
conditions.
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METHODS
Animals
Studies were performed in female Wistar rats (8 weeks
old, derived from the Wistar rat colony at Westmead Hos-
pital). Animals were fed standard rat pellets and allowed
tap water ad libitum. All protocols were approved by the
Animal Ethics Committee, Westmead Hospital, Univer-
sity of Sydney, and animals were handled according to the
guidelines of the National Health and Medical Research
Council of Australia.
Experimental design
In the first study, animals were divided into four groups
according to body weight: (1) control group [saline +
dimethyl sulfoxide (DMSO)] (N= 4); (2) protein over-
load nephropathy + DMSO (N= 9); (3) protein overload
nephropathy + rapamycin (0.2 mg/kg) (Sigma-Aldrich,
Sydney, Australia) (N= 9); and (4) protein overload
nephropathy + roscovitine (3.5 mg/kg) (Sigma-Aldrich)
(N= 9). Protein overload nephropathy was induced by
daily intraperitoneal injections of BSA (2.1 g) (A4503)
(Sigma-Aldrich) under halothane anesthesia on days 0,
1, 2, and 3, as previously described [12]. Endotoxin was
assessed in the injected BSA solution and found to be
significantly below levels that increase glomerular per-
meability or cause tubular injury (0.03 lg/mL) (Kinetic
Chromogenic Test) (assessed independently by AMS
Laboratories Pty. Ltd., Sydney, Australia) [13]. The ex-
perimental drugs were administered daily by intraperi-
toneal injection 3 days prior to and then on each day of
the BSA injections (that is, from day −3 through to day
+3). Roscovitine is a small molecule cyclin-dependent ki-
nase inhibitor [15] and is a potent suppressor of mesangial
cell proliferation in the Thy1 model of glomerulonephri-
tis [14]. It was included in the study to investigate whether
it could inhibit tubular epithelial cell proliferation, and if
so, whether this caused the same pathologic effects as ra-
pamycin. For the control group, BSA and the experimen-
tal drug, were substituted with normal sterile saline and
DMSO (the vehicle), respectively. The dose, route, and
frequency of rapamycin and roscovitine administration
were determined according to previous studies in rats [9,
14]. Doses of roscovitine higher than 3.5 mg/kg were not
used as they cause toxic side effects in rats [14].
On day 2, nonfasting animals were placed in metabolic
cages for 14 hours to determine urinary protein excre-
tion. On day 3, approximately 3 hours after the final BSA
injection, animals received a single intraperitoneal in-
jection of 5-bromo-2′-deoxyuridine (BrdU) (50 mg/kg).
Three hours later, animals were anesthetized with ke-
tamine:xylazine. A midline laparotomy was performed,
blood was collected by cardiac puncture, the inferior vena
and aorta were transected below the renal arteries, and
nephrectomys were performed. Day 3 was chosen as the
end of the study as preliminary experiments in our lab-
oratory showed that tubular epithelial cell proliferation
peaks between days 3 and 4 in this model.
To determine the effect of rapamycin on kidney struc-
ture and function in normal rats, in a second study,
groups received either vehicle (DMSO) or rapamycin
(0.2 mg/kg) (Sigma-Aldrich) (N= 9) for the same du-
ration as in experiment 1 (that is, 6 days). Blood, urine,
and kidney tissue were collected as described in the first
experiment. In addition, trough levels of rapamycin were
assessed in whole blood, collected 6 hours after the last
injection of rapamycin, by a high-performance liquid
chromatography (HPLC) assay (Department of Clinical
Pharmacology, Westmead Hospital).
Renal function
The serum creatinine, albumin, cholesterol, urinary
protein, and urinary creatinine were assessed by an auto-
analyser, as previously described [16].
Histology and immunohistochemistry
For histologic analysis midcoronal sections of kid-
ney were fixed in either neutral buffered formalin or
methyl carnoy and embedded in paraffin. Sections 3 lm in
thickness were stained by the periodic acid-Schiff (PAS)
method. For immunohistochemistry, sections were pro-
cessed according to standard protocols and incubated
with primary antibody (16 hours at 4◦C) as previously de-
scribed [16]. The primary antibodies used were anti-BrdU
(Amersham Biosciences, Sydney, Australia), anti-rat
monocyte/macrophage (ED1) (Serotec, UK), anti-cyclin
D1 (Neomarkers, Lab Vision, Fremont, CA, USA), anti-
cyclin D3 (Neomarkers, Lab Vision), and anti-p27kip1
(Neomarkers, Lab Vision). Immunostaining for cyclin D1
and cyclin D3 required antigen unmasking in formalin-
fixed sections with microwave heating for 5 minutes in
citrate buffer (Antigen Decloaker) (Biocorta, San Diego,
CA, USA), prior to application of the primary antibody.
For p27kip1, antigen unmasking in formalin-fixed sections
consisted of microwave heating for eight rounds in dis-
tilled water, before application of the primary antibody.
A negative control (primary antibody omitted) was in-
cluded in all experiments.
Assessment of tubular epithelial cell apoptosis
Tubular epithelial cell apoptosis was evaluated by the
in situ cell death detection terminal deoxynucleotidyl
transferase (TdT)-mediated deoxyuridine triphosphate
(dUTP) nick end-labeling (TUNEL) method using a
commercial kit (Roche Diagnostics, Sydney, Australia)
on formalin-fixed slides according to the manufacturer’s
instruction. Permeabilization was achieved with pro-
teinase K (20 lg/mL) treatment. TUNEL-positive cells
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Table 1. Biochemical data and kidney weight in the experimental groups
Kidney
Serum Serum Urine weight:body
creatinine Serum cholesterol Proteinuria protein:creatinine Kidney weight
Group Number lmol/L albumin g/L mmol/L mg/day ratio mg/mmol weight g ratio g/100 g
Saline + DMSO 4 26 ± 1 35 ± 1 2.3 ± 0.1 11 ± 0.1 0.21 ± 0.06 0.84 ± 0.07 0.39 ± 0.02
Protein overload nephropathy
+ DMSO
9 117 ± 27a 76 ± 4a 1.5 ± 0.1a 1074 ± 188a 20.8 ± 2.1a 1.50 ± 0.34a 0.68 ± 0.07a
Protein overload nephropathy
+ rapamycinc
9 353 ± 54a,b 89 ± 5a 2.7 ± 0.4b 836 ± 194a 15.1 ± 2.5a 1.42 ± 0.14a 0.62 ± 0.05a
Protein overload nephropathy
+ roscovitine
9 73 ± 11a 70 ± 1a 1.7 ± 0.1a 1449 ± 187a 20.8 ± 2.7a 0.74 ± 0.07a,b 0.53 ± 0.02a
DMSO is dimethyl sulfoxide. Data are expressed as mean ± SEM.
aP < 0.05 versus control + vehicle; bP < 0.05 versus protein overload nephropathy + vehicle; cIn the protein overload nephropathy + rapamycin group, the data for
proteinuria and urine protein:creatinine ratio are for seven animals only as one animal was euthanized on day 2 before urine could be obtained and another was anuric
on the day of urine collection.
were visualized with diaminobenzidine (DAB). Positive
and negative controls were prepared as recommended by
the manufacturer. TUNEL-positive cells were defined,
according to strict criteria, as DAB-positive cells with
morphologic features of apoptosis.
Quantification of immunohistology
Random selection methods were used to determine
the microscopic fields for evaluation. To assess cortical
tubulointerstitial injury the average of a semiquantitative
score in five cortical fields (×200) where 0 was no tubu-
lointerstitial injury (tubular dilatation, tubular injury, and
interstitial volume expansion); 1 was 1% to 25% of the
field contained tubulointerstitial injury; 2 was 26% to
50% of the field contained tubulointerstitial injury; 3
was 51% to 75% of the field contained tubulointersti-
tial injury; and 4 was 76% to 100% of the field con-
tained tubulointerstitial injury. To independently assess
intratubular protein cast formation a semiquantitative
score was measured in five cortical fields (×200) where
0 was no casts present in cortical tubules; 1was 25% of
cortical tubules contained casts; 2 was 50% of cortical
tubules contained casts; 3 was 75% of cortical tubules con-
tained casts; and 4 was 100% of cortical tubules contained
casts. For BrdU, TUNEL, cyclin D1, and cyclin D3, the
number of DAB-positive tubular epithelial cells/nuclei
were counted in ten overlapping cortical fields (×200).
For ED1, the number of DAB-positive interstitial cells
were counted in ten overlapping cortical fields (×200).
To assess the cortical expression of p27kip1, quantitative
image analysis was performed (Optimas 6.51) (Media Cy-
bernetics, Silver Spring, MD, USA). The percentage area
positive for DAB was calculated from the mean of ten
cortical fields (×400) for each animal.
Statistics
Data were analyzed using the JMP software package
(SAS Institute, Cary, NC, USA). Multiple parametric and
nonparametric comparisons were performed using one-
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Fig. 1. Creatinine clearance in the experimental groups. ∗P < 0.05
when compared to control + dimethyl sulfoxide (DMSO); #P < 0.05
when compared to protein overload nephropathy (PON) + DMSO.
Mean ± SEM. Abbreviations are: Rapa, rapamycin; Rosco, roscovitine.
way analysis of variance (ANOVA) with two-sample t test
and the Kruskal-Wallis test. A P value less than 0.05 in-
dicated significance. Unless otherwise state, data were
expressed as mean ± SEM.
RESULTS
Rapamycin causes acute renal failure in protein overload
nephropathy
The repeated administration of rapamycin or roscovi-
tine did not affect body weight in rats with protein over-
load nephropathy (DMSO 225 ± 7; rapamycin 230 ± 7;
and roscovitine 235 ± 4 g on day 3). However, one rat
in the rapamycin-treated group was euthanized on day 2
due to signs of physical distress, and another was anuric
at the time of urine collection. Biochemical and protein-
uria data are shown in Table 1. Rapamycin caused severe
acute renal failure (as determined by the serum crea-
tinine and creatinine clearance) and mild hypercholes-
terolemia, but did not significantly alter proteinuria (as
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Fig. 2. Photomicrographs of the renal cortex from the experimental groups. Protein overload nephropathy (PON) was characterized by tubular
dilatation, interstitial edema, and inflammation with some cast formation. In the rapamycin-treated group, there was a dramatic increase in
intratubular cast formation. Bowman’s space was filled with proteinaceous material and proximal tubular epithelial cells were swollen with increased
intracytoplasmic protein droplets (arrow) [periodic acid-Schiff (PAS) magnification ×50, ×200, ×400). DMSO is dimethyl sulfoxide.
determined either by the timed collection or the urinary
protein:creatinine ratio) (Fig. 1) (Table 1). In contrast,
roscovitine attenuated renal dysfunction as assessed by
creatinine clearance (P < 0.05) and there was a trend for
a decrease in the serum creatinine.
Rapamycin increases intratubular cast formation
in protein overload nephropathy
In PAS-stained sections, protein overload nephropathy
was characterised by tubular dilatation, interstitial edema
and inflammation with cast formation, compared to the
control group (saline + DMSO) (Fig. 2). Rapamycin
treatment worsened renal cortical tubulointerstitial in-
jury (Fig. 2) (mean tubulointerstitial injury score: protein
overload nephropathy + DMSO 2.6 ± 0.2; protein over-
load nephropathy + rapamycin 3.4 ± 0.3) (P < 0.05). This
was characterized by a dramatic increase in the number of
intratubular proteinaceous casts, consisting of homoge-
nous eosinophilic material (protein overload nephropa-
thy + DMSO 1.7 ± 0.3; protein overload nephropathy +
rapamycin 2.9 ± 1.3) (P = 0.02). In five of the nine protein
overload nephropathy animals treated with rapamycin,
the cast formation was severe and diffuse throughout
the cortex and medulla. In some areas, Bowman’s space
of glomeruli was also filled with proteinaceous material
(Fig. 2). In contrast to rapamycin, there was a trend for
an improvement in the roscovitine-treated group (2.1 ±
0.2) (P = 0.07).
Rapamycin increases cytoplasmic protein absorption
droplets in tubular epithelial cells
Proximal tubular epithelial cells from rats treated with
rapamycin were swollen and engorged with increased
intracytoplasmic protein droplets (Fig. 2). Very occa-
sionally, tubular epithelial cells were detached from the
basement membrane and present in the lumen in the
rapamycin-treated animals, but no areas of necrosis were
seen.
Rapamycin reduces cortical tubular epithelial cell
proliferation but does not affect apoptosis in protein
overload nephropathy
Kidneys from rats with protein overload nephropa-
thy had a granular surface and increased in weight by
almost twofold (Table 1). The proliferation of cortical
tubular epithelial cells (assessed by the number of BrdU-
positive nuclei) was increased by more than 20-fold in
the vehicle-treated protein overload nephropathy group,
and reduced by almost 65% with rapamycin treatment
(Fig. 3). There was a nonsignificant trend for roscovitine
to reduce tubular epithelial cell proliferation (P = 0.22).
The number of TUNEL-positive tubular epithelial cells
was increased in protein overload nephropathy (saline
+ DMSO 2.1 ± 0.4 cells per field and protein overload
nephropathy + DMSO 3.7 ± 0.5 cells per field) (P <
0.05), as shown previously [12], but this not altered by
rapamycin (4.0 ± 0.4) or roscovitine (3.2 ± 0.8).
Rapamycin does not alter D-type cyclin expression in
tubular epithelial cells
To investigate the molecular mechanisms of
rapamycin-mediated suppression of tubular epithe-
lial cell proliferation in protein overload nephropathy,
the expression of D-type cyclins (which promotes the
G1/S phase transition of the cell cycle) was examined.
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Fig. 3. Photomicrographs and quantitation of the renal cortex. (A) Photomicrographs show 5-bromo-2′-deoxyuridine (BrdU)-positive tubular
epithelial cells (TECs) (×200). Abbreviations are: PON, protein overload nephropathy; DMSO, dimethyl sulfoxide. (B) Quantitation of the number
of BrdU-positive cortical tubular epithelial cells (mean ± SD). ∗P < 0.05 compared to protein overload nephropathy + DMSO [diaminobenzidine
((DAB) with methyl green counterstain, magnification ×200].
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Fig. 4. Photomicrographs and quantitation of the renal cortex. (A) Photomicrographs show cyclin D1 (upper panels) and cyclin D3 (lower panels)
immunostaining in the experimental groups [diaminobenzidine (DAB) with methyl green counterstain, magnification ×200]. Both cyclin D1 and D3
were detected in the nuclei of multiple tubular epithelial cells (arrows). Abbreviations are: PON, protein overload nephropathy; DMSO, dimethyl
sulfoxide. (B) Quantitation of the number of cyclin D1- or cyclin D3-positive tubular epithelial cells (mean ± SE). Abbreviations are: Rapa,
rapamycin; Rosco, roscovitine. ∗P < 0.05 compared to the control group (saline + DMSO).
By immunohistochemistry, cyclin D1 and cyclin D3
protein were constitutively expressed in the nuclei of
tubular epithelial cells in control animals (Fig. 4A). In
protein overload nephropathy, the number of cyclin
D1-positive, but not cyclin D3-positive tubular epithelial
cells was reduced in protein overload nephropathy on
day 3 compared to the control group (P = 0.03). The
expression of cyclin D-type cyclins in tubular epithelial
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Fig. 5. Photomicrographs and quantitation of the renal cortex. (A) Photomicrographs show p27kip1 (upper panels, ×200; lower panels, ×400)
immunostaining in the experimental group. p27kip1 was detected in the nuclei of multiple tubular epithelial cells (arrows) in all groups. In the
rapamycin-treated group, p27kip1 was increased and also expressed in the cytosol of tubular epithelial cells. Abbreviations are: PON, protein
overload nephropathy; DMSO dimethyl sulfoxide. (B) Quantitation of cortical p27kip1 expression (percentage, mean cortical field (mean ± SE).
Abbreviations are: Rapa, rapamycin; Rosco, roscovitine. ∗P < 0.05 compared to the protein overload nephropathy + DMSO.
Normal+DMSO Normal+Rapamycin
Fig. 6. Photomicrographs of the renal cor-
tex of normal rats treated with either vehicle
[dimethyl sulfoxide (DMSO)] or rapamycin
for 6 days. Rapamycin did not induce in-
tratubular protein cast formation in normal
rats [periodic acid-Sciff (PAS) magnification
×200].
cells in protein overload nephropathy, however, were not
altered by rapamycin or roscovitine treatment (Fig. 4).
Rapamycin increases p27kip1 in tubular epithelial cells in
protein overload nephropathy
In some cell types, rapamycin up-regulates the G1/S
transition cyclin-dependent kinase inhibitor, p27kip1. To
test this hypothesis in protein overload nephropathy,
immunostaining for p27kip1 was performed. In control
animals, nuclear staining for p27kip1 was constituitively
present in the nuclei of cortical tubular epithelial cells
(Fig. 5). There was a trend for tubular epithelial cell
p27kip1 to be reduced in protein overload nephropathy
animals treated with the vehicle. Rapamycin treatment,
however, increased p27kip1 protein expression in tubular
epithelial cells (P < 0.05). Under these circumstances,
p27kip1 was present not only in the nucleus but also in the
cytosol of tubular epithelial cells (Fig. 5A). Roscovitine
did not significantly alter p27kip1 expression in tubular
epithelial cells.
Rapamycin and roscovitine reduce interstitial monocyte
accumulation in protein overload nephropathy
Interstitial monocyte accumulation was increased al-
most twofold in protein overload nephropathy, as as-
sessed by ED1 immunohistochemistry (saline + DMSO
25.6 ± 7.5 cells/mm2 and protein overload nephropathy
+ DMSO 49.5 ± 5.0 cells/mm2) (P < 0.05). Both ra-
pamycin and roscovitine reduced interstitial monocyte
accumulation in protein overload nephropathy (protein
overload nephropathy + rapamycin 16.2 ± 5.0 cells/mm2
and protein overload nephropathy + roscovitine 30.8 ±
5.0 cells/mm2) (P < 0.05 compared to protein overload
nephropathy + DMSO).
Rapamycin does not cause acute renal failure or cast
nephropathy in normal rats
In normal rats, treatment with rapamycin increased the
serum cholesterol (normal + DMSO 1.5 ± 0.1 mmol/L
and normal + rapamycin 2.1 ± 0.1 mmol/L) (P < 0.01)
but did not alter serum creatinine (normal + DMSO 33 ±
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5 lmol/L and normal + rapamycin 30 ± 3 lmol/L), pro-
teinuria (normal + DMSO 6 ± 1 mg/day and normal +
rapamycin 7 ± 6 mg/day), or induce intratubular pro-
tein cast formation in normal rats (Fig. 6). The mean
trough levels in whole blood achieved with this dose of
rapamycin was 10.3 ± 1.2 ng/mL.
DISCUSSION
The main findings of the present study were (1) ra-
pamycin caused severe acute renal failure in protein over-
load nephropathy; (2) rapamycin increased intratubular
protein cast formation and appeared to disrupt the intra-
cytoplasmic processing of proteins in tubular epithelial
cells in protein overload nephropathy; (3) rapamycin in-
hibited proteinuria-induced tubular epithelial cell prolif-
eration in vivo, through a mechanism that may involve
the upregulation of p27kip1; and (4) the adverse patho-
logic renal effects of rapamycin were specific to protein
overload nephropathy, as they did not occur in normal
rats given identical and therapeutically relevant doses of
rapamycin.
In previous preclinical studies, the effects of rapamycin
on renal function and structure have been extensively ex-
amined in normal rats [1]. However, these studies did not
reveal whether rapamycin had any unique effects on kid-
ney pathophysiology in proteinuric conditions. Fervenza
et al [8] recently reported that rapamycin caused func-
tional nephrotoxicity in humans with glomerular disease.
In addition, another study also recently reported that ra-
pamycin use was associated with the continuing deteri-
oration of renal function, in kidney transplant patients
with chronic allograft nephropathy whose baseline pro-
teinuria was greater than 1.5 g per day [17]. In contrast,
in patients with proteinuria lower than this, rapamycin
improved graft function at 12 months [17]. However,
the question as to whether rapamycin had any specific
pathologic effects in the kidney in proteinuric conditions
had not been addressed. The results of the current study
provide the first experimental evidence to suggest that
rapamycin nephrotoxicity in proteinuric renal diseases
could, in some circumstances, be due to a unique pattern
of pathologic injury involving the induction of protein
cast nephropathy.
It is well known that rapamycin exacerbates renal func-
tion in experimental models of acute renal ischemia,
through mechanisms that involve impaired tubular ep-
ithelial cell regeneration and increased apoptosis [9].
However, the pathogenesis of functional nephrotoxicity
in protein overload nephropathy appears to be different.
Consistent with previous observations in rats with acute
renal ischemia [9], rapamycin reduced tubular epithelial
cell proliferation but, in contrast, did not increase tubular
epithelial cell apoptosis in protein overload nephropa-
thy [9]. Rather, increased intratubular protein cast for-
mation was the most dramatic histologic feature of ra-
pamycin treatment in protein overload nephropathy. Cast
formation was quite diffuse and widespread in more than
50% of the animals. In some areas, Bowman’s space was
filled with proteinaceous material. The latter supports
the possibility that the acute renal failure was the con-
sequence of intratubular obstruction secondary to cast
nephropathy. The nephrotoxicity of rapamycin in protein
overload nephropathy seems to be pathologically analo-
gous to other types of acute renal failure that are medi-
ated by protein-induced intratubular obstruction, such as
rhabdomyolysis, acute tumor cell lysis, and paraprotein-
associated kidney disease in humans [18, 19].
The mechanisms by which rapamycin promotes protein
cast formation in protein overload nephropathy require
further investigation. Interestingly, increased intratubu-
lar cast formation was also present in kidney biopsies
from renal transplant patients with delayed graft func-
tion who received rapamycin [20]. In the latter study, it
was hypothesised that denuded tubular epithelial cells
might act as a nidus for cast formation in the lumen. How-
ever, in our study in protein overload nephropathy, de-
tached tubular epithelial cells in association with luminal
casts (which were very eosinophilic and homogenous)
were rarely present. Instead, another striking morpho-
logic feature in the rapamycin-treated protein overload
nephropathy group was that some proximal tubular ep-
ithelial cells were swollen and engorged with increased
cytoplasmic protein droplets. These morphologic ob-
servations suggest that rapamycin (through effects on
mTOR) disrupted the intracellular processing of endo-
cytosed proteins in tubular epithelial cells, as suspected
from in vitro studies by Dixon and Brunskill [21]. Alter-
natively, reduced tubular epithelial cell proliferation may
also have decreased the overall capacity of the nephron to
process the increased concentration of albumin in tubu-
lar lumen. Whatever the exact pathogenesis, we postu-
late that the end result was an increase in the amount of
luminal protein reaching the distal tubule, thereby pro-
moting protein aggregation and cast formation. Indeed,
rapamycin has been reported to increase proteinuria in
some transplant recipients [17, 22], and our data raise the
hypothesis that this might, at least in part, be mediated
by a tubular mechanism.
To investigate the molecular mechanisms of the an-
tiproliferative effect of rapamycin in tubular epithelial
cells, the expression of D-type cyclins and p27kip1 in pro-
tein overload nephropathy was determined. D-type cy-
clins promote the G1/S phase transition of the cell cycle.
In some cell types D-type cyclin expression can be sup-
pressed by rapamycin [23–25], but this was not the mech-
anism in protein overload nephropathy. Instead, our data
clearly show that rapamycin increased the protein expres-
sion of p27kip1 in cortical tubular epithelial cells. This ob-
servation is consistent with previously known effects of
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rapamycin [26]. Interestingly, rapamycin altered the sub-
cellular localization of p27kip1 and caused a significant
increase in expression in the cytosol of tubular epithelial
cells.
In contrast to rapamycin, roscovitine failed to reduce
tubular epithelial cell proliferation in protein overload
nephropathy, despite being used at doses appropriate to
suppress mesangial cell proliferation in rats [14]. Yet,
roscovitine conferred partial functional and histologic
protection in protein overload nephropathy, most likely
due to the anti-inflammatory effects of this compound.
On the other hand, rapamycin also reduced mono-
cyte accumulation. Therefore, the divergent effects of
rapamycin and roscovitine in protein overload nephropa-
thy, again emphasize that tubular epithelial cell prolifer-
ation is an important compensatory response during the
early phase of this model.
In contrast to the results of the current study, ra-
pamycin was renoprotective in the passive Heymann
nephritis rat model of membranous nephropathy [27],
and in the Han:Sprd model of polycystic kidney dis-
ease [28]. Moreover, unpublished data from our labo-
ratory also show that chronic rapamycin treatment for
up to 6 weeks reduces renal hypertrophy and does not
induce cast nephropathy in adriamycin nephropathy (a
toxin-induced model of FSGS). These data suggest that
rapamycin-mediated nephrotoxicity in glomerular dis-
ease is complex and could be determined by the rapid-
ity and severity of the proteinuria (which is very high
in protein overload nephropathy compared to Heymann
nephritis and adriamycin nephropathy), the composition
of the proteinuria as well as other disease-specific factors.
These intriguing observations warrant further investiga-
tion in future studies, as it may help define the risk factors
for developing rapamycin-induced nephrotoxicity in hu-
man glomerular disease [29].
CONCLUSION
Rapamycin causes acute renal failure in protein over-
load nephropathy due to a specific pattern of renal injury
characterized by intratubular obstruction secondary to
increased protein cast formation. The latter could be due
to disruption of a potentially important compensatory
mechanism in nephrotic glomerular disease involving
tubular epithelial cell protein endocytosis and prolifer-
ation. Moreover, in resembling recent clinical reports [8,
17, 20, 22, 29], these data raise further caution in the
use of rapamycin in glomerular diseases characterized
by nephrotic range proteinuria, until further information
is available [29].
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